Skip to main content
Premium Trial:

Request an Annual Quote

Phthisis Diagnostics Raises $410,000

NEW YORK (GenomeWeb News) – Phthisis Diagnostics announced recently it has raised $410,000 in a second round of angel funding.

The money will be used to continue marketing its products and to expand its product lines, Crystal Icenhour, president and CSO of the Charlottesville, Va.-based company said. The money will go toward completing the development and clinical trials for Phthisis' first diagnostic for parasites, which is expected to be launched within the next 18 months, she added, and additional diagnostics for fungi mycobacterium, as well as molecular standards for improved laboratory quality control, are also being developed.

Original investors in the firm, Piedmont Angel Network and New Dominion Angels, contributed $147,500 to the round, while seven other investors committed an additional $262,500. New investors in the round include Piedmont Investment Advisors, through its affiliate Militello Capital; MooDoos Limited Partnership; Ronald Harris; Virga Ventures; Daniel Brody; and Afton Scientific NA.

The Scan

Not Yet a Permanent One

NPR says the lack of a permanent Food and Drug Administration commissioner has "flummoxed" public health officials.

Unfair Targeting

Technology Review writes that a new report says the US has been unfairly targeting Chinese and Chinese-American individuals in economic espionage cases.

Limited Rapid Testing

The New York Times wonders why rapid tests for COVID-19 are not widely available in the US.

Genome Research Papers on IPAFinder, Structural Variant Expression Effects, Single-Cell RNA-Seq Markers

In Genome Research this week: IPAFinder method to detect intronic polyadenylation, influence of structural variants on gene expression, and more.